Trial · NCT06588504
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adults cohort: Time to plasma glucose (PG) recovery, where PG recovery is defined as the first increase in PG of greater than or equal to (>=) 20 milligrams per decilitre (mg/dL) (1.1 millimoles per litre [mmol/L]) from baseline | From 0 to 90 minutes after investigational medicinal product (IMP) injection | Measured in minutes. |
| Secondary | Adolescent cohort: Time to PG recovery, where PG recovery is defined as the first increase in PG of >=20 mg/dL (1.1 mmol/L) from baseline | From 0 to 90 minutes after IMP injection | Measured in minutes. |
| Secondary | PG recovery within 30 minutes after IMP injection (yes/no) | From 0 to 30 minutes after IMP injection | Measured in count of participant. |
| Secondary | PG recovery within 20 minutes after IMP injection (yes/no) | From 0 to 20 minutes after IMP injection | Measured in count of participant. |
| Secondary | PG recovery within 15 minutes after IMP injection (yes/no) | From 0 to 15 minutes after IMP injection | Measured in count of participant. |
| Secondary | PG change from baseline at 15 minutes after IMP injection | From 0 to 15 minutes after IMP injection | Measured in milligrams per deciliter (mg/dL). |
| Secondary | PG change from baseline at 20 minutes after IMP injection | From 0 to 20 minutes after IMP injection | Measured in mg/dL. |
| Secondary | Area under the plasma dasiglucagon concentration time curve after IMP injection | On Day 1 after injection | Measured in hour\*picomoles per liter (h\*pmol/L). |
| Secondary | Maximum observed plasma (Cmax) dasiglucagon concentration | From 0 to 5 hours after IMP injection | Measured in pmol/L. |
| Secondary | Number of adverse events (AEs) | From IMP injection (visit 2 day 1 and visit 3 day 1) until 28 days after IMP injection | Measured in number of events. |
| Secondary | Number of hypoglycaemic episodes | From IMP injection (visit 2 day 1 and visit 3 day 1) until 12 hours after IMP injection | Measured in number of episodes. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06588504/registered